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CA Novel Treatment Using an Intraventricular Stent Graft for
Postinfarction Ventricular Septal Rupture in a Porcine ModelYuji Nishida, MD, Shigeyuki Tomita, MD, PhD, Ryuta Kiuchi, MD, PhD,
Hiroshi Ohtake, MD, PhD, and Go Watanabe, MD, PhDObjective:Ventricular septal rupture (VSR) is a severe complication of
acute myocardial infarction, and the conventional technique for repair is
associated with high operative mortality. A novel intraventricular stent
graft (IVSG) device was tested as a less invasive treatment for VSR; it
does not require cardiopulmonary bypass, cardiac arrest, or left ventric-
ular incision. Its effectiveness was assessed using animal experiments.
Methods: Six pigs were placed on cardiopulmonary bypass. The VSR
model was created by making a hole in the interventricular septum via
the right ventricle. Animals were weaned off the bypass. The sheath
encasing the device was advanced over the guidewire, and the IVSG
was placed in the left ventricle. Before and after rupture creation
and after device deployment, left ventriculography was performed, he-
modynamic data were collected, and Qp/Qs values were measured.
Results: All procedures were completed safely. The left-to-right shunt
seen after rupture creation disappeared after device deployment. The
pulmonary-to-systemic blood flow ratio after rupture was 3.35 ± 1.00,
decreasing significantly to 1.09 ± 0.10 after device deployment
(P = 0.007). Hemodynamic instability after rupture creation improved
dramatically after deployment.
Conclusions: The use of our new IVSG in this VSR animal experiment
model significantly decreased the left-to-right shunt. The new device
was able to control the acute heart failure associated with VSR with a
minimally invasive procedure during the hyperacute phase of heart
failure. Potential improvements in VSR treatment outcomes are expected
with its clinical application.
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opyright © 2017 by the International Society for Minimally Invasive CardioVentricular septal rupture (VSR) is a complication observedin 0.2% to 2% of acute myocardial infarctions and can lead
to severe, acute, bilateral heart failure due to the onset of a severe
left-to-right (L-R) shunt.1 The mortality rate with medical ther-
apy alone is 50% within 1 week and as high as 90% within
1 month.2,3 Currently, intracardiac repair by inducing cardiac ar-
rest with thoracotomy and extracorporeal circulation is the most
common procedure; however, the risk associated with this sur-
gery is equivalent to that in the acute phase of acute myocardial
infarction. The surgical procedure itself is difficult because of
preoperative factors, such as very poor cardiac function, exces-
sive invasiveness, and the instability of the repair; the operative
mortality rate is 20% to 87% despite advances in surgical
techniques.1–5 We think that the factors related to the poor re-
sults with the conventional methods are the excessive invasion
of extracorporeal circulation in the acute phase of myocardial in-
farction and the cardiac dysfunction due to cardiac arrest during the
operation and left ventricular (LV) direct incision. We contrived a
new, less invasive treatment option for VSR that does not require
extracorporeal circulation, cardiac arrest, or LV incision.
The salient features of this new device, including VSR
closure from the LV, catheter insertion in a beating heart, its abil-
ity to follow LV wall movement because of its flexible structure,
and decreased interference with the mitral valve chordae
tendineae, are presented. Previously, we reported a case of the
clinical application of this technique based on this research.6
In the present study, its effectiveness as a new surgical procedure
for VSR was evaluated in animal experiments.MATERIAL AND METHODS
Construction of the Intraventricular Stent Graft
The intraventricular stent graft (IVSG) was designed to fit
the LV structure of a pig weighing 60 to 70 kg. The design pro-
cess involved the development of several different shapes and
the selection of the optimal shape in pig-heart model experi-
ments. Because stent graft interference with mitral valve tissue
results in severe mitral regurgitation (MR), a slant cup shape
was adopted, which decreased the interference with the mitral
valve. The results of these basic animal experiments are cur-
rently being presented in a separate article.
The measurements required to determine the size of the
IVSG were left ventricular dimension diastolic (LVDd), short
side length, and long side length (Figs. 1A, B). The device diam-
eter was established as approximately 1.1 LVDd. The diameter
of the device used in this study was 36.6 ± 2.4 mm. The IVSG
was set to the desired axis of implantation between the cardiac21
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FIGURE 1. Design of the IVSG. A, B, Three measurements of LVDd, short side height, and long side height are needed to choose the
optimal size of the IVSG. The device diameter was set up as approximately 1.1 LVDd. The short side extends from the cardiac apex to
overlap 10mm from the base of the papillarymuscle. The long side extends from the cardiac apex to 10mmormore from the outflow side
edge of the VSR. The 10-mm zone above the VSR is termed the landing zone. The IVSG end toward the cardiac apex has a tubular
anchoring port to facilitate the passage of devices such as guidewires. This port is ultimately used to fix the device to the cardiac apex. C,
The framework for the IVSG is a superelastic nitinol stent shaped in a slant cup style. D, The IVSG is covered by polyester woven graft.
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Capex, where the stent was placed, and the center of the aortic
valve. The lengths of the short and long sides were measured
using a line that crossed this axis at right angles. The short side
extended from the cardiac apex to overlap 10 mm from the base
of the papillary muscle. The long side extended from the cardiac
apex to 10 mm or more from the outflow side edge of the VSR.
The 10-mm zone above the VSR was termed the landing zone.
The IVSG end toward the cardiac apex had a tubular anchoring
port to facilitate the passage of devices such as guidewires. This
port was ultimately used to fix the device to the cardiac apex.
The framework for the IVSG is theMatsui-Kitamura (MK)
stent (Fig. 1C), which is made from a single 0.35-mm-diameter
superelastic alloy wire (Memoalloy; Tokin Inc, Tokyo, Japan)
containing 51% nickel and 49% titanium by weight, and having22 Copyright © 2017 by th
opyright © 2017 by the International Society for Minimally Invasive Cardioa transformation temperature of less than 0°C. The nitinol wire
was wound in a spiral fashion around a cup type stainless steel
mandrel. The stent was annealed at 350°C in an oven for
25 minutes and then cooled to room temperature. The nitinol frame-
workwas then removed from themandrel, and both ends of themono
wire were connected with a small, compressed platinum cylinder.
The intraventricular stent was covered with a seamless,
cup-shaped, woven graft made of polyester fabric (Kitamura
Manufacturing, Niigata, Japan) with a thickness of 0.2 mm
(Fig. 1D). The porosity of the polyester fabric was approximately
100 mL/min/cm2. The graft was attached to the stent with 5–0
interrupted polypropylene sutures. Platinum markers were at-
tached to the anterior and posterior sides of the graft with 5–0
interrupted polypropylene sutures.e International Society for Minimally Invasive Cardiothoracic Surgery
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CThe IVSGs of diameter of 40mmor less were placed in an
18-F sheath (Flexor Keller-Timmermans Introducer; CookMed-
ical, Bloomington, IN USA) to facilitate delivery. The IVSGs of
diameter of more than 40 mm can be passed in a 20-F sheath.
Operative Procedure
This procedure was performed on 6 consecutive Yorkshire
pigs. All animals received humane care in compliance with the
Guide for the Care and Use of Laboratory Animals (www.
nap.edu/catalog/5140.html) at the Takaramachi Campus of
Kanazawa University.
The 6 pigs [mean ± standard deviation (SD) weight,
66.8 ± 4.5 kg] were sedated by means of an intramuscular in-
jection of ketamine (10 mg/kg body weight). Anesthesia was
maintained with 0.5% to 1.5% halothane in a mixture of oxy-
gen, nitrous oxide gas, and intravenously injected propofol
(1–2 mg/h/kg body weight) and pancuronium bromide
(0.04 mg/kg body weight). The rate and volume of positive
pressure ventilation (KMA-1300 IIS; ACOMA, Tokyo,
Japan) were adjusted to maintain the arterial blood gases
within the normal physiological range. Electrocardiographic
monitoring was performed throughout the procedure. A median
sternotomy was performed, and the pericardium was opened
longitudinally along the midline. A cannula was placed in the
common femoral artery, the main pulmonary artery, and the su-
perior vena cava, and the systemic arterial pressure, pulmonary
arterial pressure, and central venous pressure were monitored
continuously. A PowerLab data acquisition system (AD Instru-
ments, Milford, MAUSA) was used for monitoring. The animal
was then heparinized by injecting 200 IU/kg of heparin. Cardio-
pulmonary bypass was established with an aortic cannula and
bicaval cannulation. Aventing catheter was inserted into the right
upper pulmonary vein. Continuous injection (2–15 μg/kg/min) of
dopamine hydrochloride was necessary in all cases. If arrhyth-
mias were easily induced before and after VSR creation, landiolol
was used as a β-blocker to prevent atrial and ventricular arrhyth-
mias before and after VSR creation.FIGURE 2. The VSRmodel and the deployment of the IVSG. A, An ant
guidewire is introduced into the (LV) apex and advanced across the a
advanced into the LV via the LV apex over the guidewire. C, Deployme
IVSG extends from the cardiac apex. The apex is closed by purse-strin
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A longitudinal incision was made on the anterior surface
of the right ventricle (RV) under total extracorporeal circulation,
with the heart still beating. AVSR was created using a 20-mm
puncher in the interventricular septum close to the RV apex
(Fig. 2A). After confirming the size of the resected septal myocar-
dium, the RVwith the longitudinal incisionwas closedwith a run-
ning 5–0 polypropylene suture. After VSR creation, the animals
were weaned off cardiopulmonary bypass (CPB) temporarily.
Intraventricular Stent Graft Deployment
Intraventricular stent graft deployment was carried out un-
der fluoroscopy. A 0.032-in guidewire (Terumo, Tokyo, Japan)
was introduced into the LVapex and advanced across the aortic
valve into the ascending aorta (Fig. 2B). A 5-F sheath (Medikit,
Tokyo, Japan) was then inserted. The 5-F angiographic catheter
was subsequently placed over the guidewire for left ventriculog-
raphy (LVG). A 0.035-in Extra-Stiff Amplatz guidewire (Cook
Medical) was introduced into the ascending aorta. After passing
the guidewire through the IVSG center, the latter was placed in
an 18-F sheath. The delivery system was advanced into the LV
via the LV apex over the guidewire. Intraventricular stent graft
deployment was performed using the anterior platinum marker
fixed to the stent to correct the direction of the stent graft to
match the direction of the VSR in the septum (Fig. 2C). No
touch-up by balloon was performed after deployment. The an-
choring ports of the IVSG penetrated the cardiac apex in one
case. In this case, the cardiac apex was closed using purse-
string sutures with felt pledgets. The anchoring port should be
fixed to the LVapex when the IVSG has to be retained; however,
fixation was not performed in this experiment.
Hemodynamics
The systemic arterial pressure, pulmonary arterial pres-
sure, central venous pressure, and pulse rate were monitored
continuously. Measured values were analyzed using the analysis
software, LabChart7 (AD Instruments). “Control” refers to theerior-type VSR is created with a right ventricular approach. B, The
ortic valve into the ascending aorta. The delivery sheath is
nt of the IVSG into the LV via the apex. The anchoring port for the
g suture with felt pledgets.
iothoracic Surgery 23
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Cphase before VSR creation, “VSR” to the phase after VSR cre-
ation, and “post-IVSG” to the phase after IVSG deployment.
The hemodynamics of the VSR were measured as soon as pos-
sible after extracorporeal circulation was withdrawn, whereas
those of post-IVSG were measured more than 30 minutes after
weaning off extracorporeal circulation.
Imaging
Left ventriculography and echocardiography were per-
formed before and after VSR creation and IVSG deployment.
Angiography was performed by inserting a sheath into the LV
apex and using a 5-F angiographic catheter before and after
VSR creation and after IVSG deployment. Intraoperative echo-
cardiography was performed via the apex or anterior RV wall di-
rectly using a gelatin gel pad.
Qp/Qs
Blood examinations of the peripheral artery, the superior
and inferior venae cavae, and the pulmonary artery before and
after VSR creation and after IVSG deployment were performed.
The oxygen saturation (SO2) of each was measured by blood gas
analysis. Blood sampling was carried out when extracorporealFIGURE 3. Hemodynamics. “Control” refers to the phase before VSR
to the phase after IVSG deployment. A, The arterial systolic blood pre
significantly after IVSG deployment. B, Pulmonary arterial systolic blo
decreases significantly after IVSG deployment. C, Central venous pres
significantly after IVSG deployment. D, The pulse rate increases signif
IVSG deployment.
24 Copyright © 2017 by th
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the right atrium and pulmonary artery was observed, and Qp/Qs
was calculated. Qp/Qs was calculated by [arterial blood SO2
(%)−mixedvenous SO2 (%)]÷ [arterial bloodSO2 (%)−pulmo-
nary artery SO2 (%)]. Mixed venous SO2 was calculated by [su-
perior vena cava blood SO2 (%)  3 + inferior vena cava SO2
(%)] ÷ 4.
Statistical Analysis
Statistical analysis was performed using IBMSPSS Statis-
tics, Version 19 J (IBM Japan, Tokyo, Japan). The data are pre-
sented as means ± SD. Comparative analysis was performed
with one-way repeated measures analysis of variance, followed
by multiple comparisons using the Bonferroni adjustment
method. Power was defined as 0.8 with a confidence interval
of 95%. P values of less than 0.05 were considered significant.
RESULTS
All procedures were completed safely, and VSR creation
and IVSG deployment were possible in all six cases. Ventricular
tachycardia occurred immediately after IVSG deployment increation, “VSR” to the phase after VSR creation, and “post-IVSG”
ssure decreases significantly after VSR creation and then increases
od pressure increases significantly after VSR creation and then
sure increases significantly after VSR creation and then decreases
icantly after VSR creation, but it is not significantly different after
e International Society for Minimally Invasive Cardiothoracic Surgery
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FIGURE 4. Left ventriculography. A, Left ventriculography shows the VSR L-R shunt flow (arrows). B, The IVSG is installed into the LV
apex. C, Post-IVSG deployment, blood flow through the VSR has stopped.
FIGURE 5. Qp/Qs. Qp/Qs deteriorates significantly because of
VSR creation and improves as expected after IVSG deployment.
The difference between control values and those after IVSG
deployment is not significant.
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Cone case, but sinus rhythmwas restored with a 10-mg intravenous
injection of xylocaine 2%. There were no intraoperative deaths.
Hemodynamics
Repeated measures analysis of variance showed a signifi-
cant effect of the procedures (control, VSR, post-IVSG) on arte-
rial systolic blood pressure (P = 0.001). Bonferroni-corrected
multiple comparisons showed that arterial systolic blood pres-
sure decreased to 65.0 ± 5.4 mm Hg, from 84.8 ± 7.6 mm Hg
of the control, after VSR creation (P = 0.002), and that it went
up to 81.3 ± 6.9 mm Hg after IVSG deployment (P = 0.035,
Fig. 3A). Pulmonary arterial systolic blood pressure increased to
38.8 ± 4.2 mm Hg after VSR creation, from 22.3 ± 2.2 mm Hg
of the control (P = 0.002). It decreased to 27.2 ± 4.3 mm Hg
after the deployment of the IVSG (P = 0.025, Fig. 3B). Al-
though central venous pressure increased from 5.2 ± 1.7 mm Hg
to 15.3 ± 2.0 mm Hg (P = 0.002), it decreased to
7.2 ± 1.6 mm Hg later (P = 0.004, Fig. 3C). The pulse rate rose
from 88.5 ± 9.8 per minute to 126.5 ± 14.9 per minute after VSR
creation (P = 0.005), and it was 119.5 ± 8.5 per minute after the
deployment of the IVSG; this difference was not significant
(P = 0.833, Fig. 3D). Any pressure study parameter showing a
worsening after VSR improved significantly after IVSG deploy-
ment. CPB could be withdrawn after VSR creation and IVSG
deployment. Maintenance of hemodynamics was difficult after
VSR creation but stabilized after IVSG deployment.
Imaging
Left ventriculography after VSR creation showed a defect
hole in the interventricular septum and the flow of the contrast
agent from the LV to the RV (Fig. 4A; Video 1, http://links.
lww.com/INNOV/A96). The IVSG was placed in the LV apex
(Fig. 4B). Left ventriculography after IVSG deployment showed
that the L-R shunt flow had disappeared, and the flow of the
contrast agent into the RV could not be seen (Fig. 4C). Left
ventriculography and echocardiography showed that the LV
apex was akinetic because of IVSG deployment, but this re-
sulted in no obvious impairment of the movement of the basal,Copyright © 2017 by the International Society for Minimally Invasive Card
opyright © 2017 by the International Society for Minimally Invasive Cardioposterior, or lateral walls. The LVejection fraction (LVEF) mea-
sured by echocardiography before and after VSR creation and
after IVSG deployment was 67.7% ± 3.2%, 69.6% ± 5.5%,
and 39.2% ± 9.8%, respectively. The LVEF after IVSG deploy-
ment was intentionally low compared with the other two
groups (P = 0.003). After IVSG deployment, significant MR,
defined as Sellers grade 2 or more, was not observed by LVG
in any case; however, Sellers grade 1 MR was observed in two
cases. Echocardiography showed mild MR in the same two
cases with LVG.
Qp/Qs
Qp/Qs of the control was 1.02 ± 0.07, and Qp/Qs after
VSR creation was 3.35 ± 1.00. Qp/Qs decreased significantly
to 1.09 ± 0.10 after IVSG deployment (Fig. 5). Qp/Qs became
significantly worse after VSR creation (P = 0.007), and it im-
proved as expected after IVSG deployment (P = 0.007). The dif-
ference between Qp/Qs of the control and that of post-IVSG
deployment was not significant (P = 0.803).iothoracic Surgery 25
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CDISCUSSION
The IVSG that was developed is a very effective device
that can decrease the L-R shunt caused by an acute myocardial
infarction–related VSR. Qp/Qs in the present VSR models was
very high, at 3.35 ± 1.00, and the L-R shunt had a negative im-
pact on the hemodynamics. The IVSGwas specifically designed
with a long septal side, so that the interventricular septum could
be covered more broadly, and a shorter posterolateral side, so
that interference with structures, such as the mitral valve and
chordae tendineae, could be decreased. Although the frame of
the MK stent has sufficient radial force to create flow control
across the ventricular defect, the flexible structure did not inter-
fere with LV function, as shown by pressure studies. We thought
that this uniquely shaped stent graft device could certainly con-
trol the shunt flow from the VSR without MR and LV dysfunc-
tion. Qp/Qs after IVSG deployment improved significantly to
1.09 ± 0.10, and the slant cup-shaped stent graft placed in the
LV dramatically decreased the amount of shunt by extensively
covering the rupture in the interventricular septum. In addition,
the hemodynamic instability that was seen after VSR creation
improved dramatically after IVSG deployment.
Surgical repair for VSR has been widely performed since
first reported by Cooley et al7 in 1957, but the operative mortal-
ity rate remains high, at 20% to 87%, despite advances in surgi-
cal techniques.1–5 There are also reports of necrotic myocardial
tissue being extremely vulnerable in the hyperacute phase of
myocardial infarction, surgical difficulty being very high, and
early surgical treatment increasing the mortality rate.2,3 Emer-
gency surgery is often necessary with the deterioration in hemo-
dynamics and general condition, despite the desire to perform
surgery in the chronic phase.8,9 In terms of hemodynamics, it
is preferable to administer treatment for VSR as soon as possible
after onset, although every effort should be made to perform
surgery during the chronic phase when tissue scarring has
progressed. Our IVSG does not require CPB and cardiac arrest.
The procedure is far less invasive than traditional intracardiac re-
pair, because placement inside the LV is possible without me-
dian sternotomy. Because vulnerable myocardial infarction foci
are isolated from high LV pressure due to the IVSG, the risk
of hemorrhage and free-wall rupture is greatly decreased. Dam-
age to cardiac function can beminimized by not performing pro-
cedures such as direct myocardial resection. On the basis of
these characteristics, early IVSG deployment may be possible
even in the hyperacute phase of cardiac failure after the onset
of myocardial infarction. Surgical repair performed during the
stage in which scarring of the myocardium has progressed and
stabilized is known to result in a good outcome.
The effectiveness of closure through placement of a per-
cutaneous obturator has been demonstrated and clinically ap-
plied in recent years as a treatment for ventricular septal defect
(VSD), which is a congenital heart disease. The Amplatzer Mus-
cular VSD Occluder (AGA Medical, Plymouth, MA USA) is
widely used.10 There have been occasional reports on VSR
closure associated with acute myocardial infarction using these
devices.11,12 This treatment is performed percutaneously, is min-
imally invasive, and has been proven to be effective. However,
the following issues have been identified.13–16 There are prob-
lems in determining the placement site because the defect holes
in the VSR associated with acute myocardial infarction are often26 Copyright © 2017 by th
opyright © 2017 by the International Society for Minimally Invasive Cardioporous. The second issue is the lack of alternative applicable de-
vices when the rupture is very large. The final issue is the possi-
bility of dislocation of the device to the RVor the embolization
of the device when fixation is insufficient, because the myocar-
dium around the VSR is often vulnerable.
At our institution, we independently developed the MK
stent graft before the widespread adoption of the thoracic
endovascular aortic repair. There have been approximately 250
cases of its clinical use.17,18 The clinical experience with the
MK stent graft has allowed us to develop the IVSG. Our IVSG
can cover a wide area, including the vulnerable ischemic myo-
cardial region, with a graft. If the location of a large VSR is
known, there is no need for detailed positioning.
The IVSGs of diameter of 40 mm or more were placed in
an 18-F sheath to facilitate delivery. The IVSGs of diameter of
40mm or more can be passed in a 20-F sheath. In the present an-
imal experiments, the devices were placed using an approach
from the LVapex where access is easier because of the fact that
the femoral arteries of the animals used were anatomically nar-
row, and thoracotomy was always required to create the VSR
models. If the deployment of the device is possible with 18- or
20-F sheaths, access from the femoral artery should be possible
in patients with standard physiques. Possible future clinical ap-
plications include approaches from the femoral artery without
sternal thoracotomy as the first choice, followed by approaches
from the LVapex via left anterior small thoracotomy, depending
on the situation. Thus, when considering 2-session LV repair and
revascularization, median sternotomy over multiple sessions can
be avoided, and the risk of chest reopening can be decreased.
The first of this study's limitations was the difference in
intraventricular shape between the experimental animal model
and humans. In particular, mitral valve tissue, such as the pap-
illary muscles and chordae tendineae, were a factor causing
severe MR associated with stent graft interference. We three-
dimensionally analyzed the LV cavities of pigs and selected a
slant cup as the optimal stent shape that caused as little interfer-
ence as possible with the mitral valve tissue, but we still need to
analyze and investigate whether the same shape is effective in
humans while performing contrast computed tomography of hu-
man LV cavities. The second limitation was that this experiment
was not conducted in an acute myocardial infarction model. Af-
ter IVSG deployment, the LVEF was intentionally low com-
pared with control. This result may be due to apex wall motion
was reduced by the stent of IVSG. However, we think that this
result is not so important in this study. Because this experiment
was not performed for acute myocardial infarction model and
the preoperative cardiac function of these cases was normal,
LV function after IVSG deployment become significantly worse
as a matter of course. The pig model of anterior myocardial in-
farction has been known to show a tendency for developing fatal
arrhythmias. It is, however, very difficult to create a VSR model
after creating an acute myocardial infarction model. Thus, the
effect of deployment of this device in the state of low LV func-
tion after myocardial infarction remains unknown. We are
waiting for the results of our chronic phase experiment for ef-
fects on LV function of IVSG. The final limitation was the un-
known durability of the IVSG. For long-term use of this
device, it will be necessary to check its durability and perform
chronic phase animal experiments. This new device may bee International Society for Minimally Invasive Cardiothoracic Surgery
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Ceffective for the intermediate period until radical surgery can be
planned. This device is suitable for installation during the early
stages of VSR onset when physicians are hesitant to perform
surgery. Left ventricular repair with median sternotomy would
then be performed at a stage several months later when cardiac
function has stabilized.
In conclusion, the L-R shunt and Qp/Qs were shown to be
significantly decreased after the deployment of our newly devel-
oped IVSG in an animal model of VSR, which is normally a fatal
complication of acute myocardial infarction. The IVSG was able
to control the acute heart failure associatedwith VSR using amin-
imally invasive procedure in the hyperacute phase of cardiac fail-
ure. Potential improvements in VSR treatment outcomes from the
clinical application of this device are awaited.
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r stent graft (IVSG) for the less invasive treatment of ventric-
ology on six pigs. The advantages of this device are that it can
ventricular incision. Ventricular septal rupture was created by
icle. This device was placed via an 18F sheath in the left ven-
e. The IVSG was placed across the VSR under fluoroscopic
loyment was possible in all six cases. Therewas no flow across
urgitation in any animal. The Qp/Qs valuewas decreased from
results.
o the study. First of all, these experiments were carried out in
the clinical situation, there is often significant muscle necro-
evices have been poor. Therefore, the relevance of this exper-
r, there was a dramatic decrease in left ventricular ejection
ental investigation. The final limitation of this study was that
t graft.
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